/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
With a market cap of $113.7 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines for oncology, hematology, immunology, cardiovascular, and neuroscience diseases. It serves patients worldwide with leading therapies such as Eliquis, Opdivo, Revlimid, Orencia, and Yervoy.
BMY is set to unveil its fiscal Q4 2025 results before the market opens on Thursday, Feb. 5. Ahead of this event, analysts expect the Princeton, New Jersey-based company to report an adjusted EPS of $1.65, down 1.2% from $1.67 in the year-ago quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters.